

# Psychedelic Inspired Medicines

January 2021

NEO  
MMED

OTCQB  
MMEDF

DE  
MMQ

# Disclaimer

## Market and Industry Data

This presentation by Mind Medicine (MindMed) Inc. (the "Presentation") includes market and industry data that has been obtained from third party sources, including industry publications. MindMed believes that the industry data is accurate and that the estimates and assumptions are reasonable, but there is no assurance as to the accuracy or completeness of this data. Third party sources generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance as to the accuracy or completeness of included information. Although the data is believed to be reliable, MindMed has not independently verified any of the data from third party sources referred to in this Presentation or ascertained the underlying economic assumptions relied upon by such sources. References in this Presentation to research reports or to articles and publications should be not construed as depicting the complete findings of the entire referenced report or article.

## CAUTIONARY NOTE ON FORWARD LOOKING INFORMATION

This Presentation contains "forward-looking statements" and "forward-looking information" within the meaning of applicable securities laws (collectively, "forward-looking information") with respect to MindMed and its subsidiaries. Statements in this Presentation that are forward-looking information are based on currently available competitive, financial, and economic data and operating plans as of the date of this Presentation but subject to various risks and uncertainties concerning the specific factors disclosed herein. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", "will", "projects", or "believes" or variations (including negative variations) of such words and phrases, or statements that certain actions, events, results or conditions "may", "could", "would", "might" or "will" be taken, occur or be achieved. Except for statements of historical fact, information contained herein constitutes forward-looking information, including, but not limited to: statements pertaining to the development and commercialization of any medicine or treatment, or the efficacy of either of the foregoing, the likelihood of success of any clinical trials or of obtaining FDA or other regulatory approval, the likelihood of obtaining patents or the efficacy of such patents once granted, and the potential for the markets that MindMed is anticipating to access.

Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management at the date the statements are made including among other things assumptions about: MindMed's ability to raise capital to complete its plans and fund its studies, the medical and commercial viability of the contemplated medicines and treatments being developed, and the ability of MindMed to raise additional capital as MindMed continues to develop its products. While MindMed considers these assumptions to be reasonable, the assumptions are inherently subject to significant business, social, economic, political, regulatory, competitive and other risks and uncertainties, contingencies and other factors that could cause actual performance, achievements, actions, events, results or conditions to be materially different from those projected in the forward-looking information. Many assumptions are based on factors and events that are not within the control of MindMed and there is no assurance they will prove to be correct.

Although MindMed has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking information, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: MindMed not being able to obtain the necessary FDA and other approvals, inconclusive or negative results from clinical trials, MindMed not electing to proceed with any of the medicines or treatments discussed herein, and MindMed not being able to build production capacity should its trials be successful.

To the extent any forward-looking information contains forecasts or financial outlooks, such information is being provided solely to enable a reader to assess MindMed's financial condition and its operational history and experience in the pharmaceutical industry. Readers are cautioned that this information may be not appropriate for any other purpose, including investment decisions. Such information, as with forward-looking information generally, is, without limitation, based on the assumptions and subject to the risks and other cautionary statements set out above. The actual results achieved will vary from the forecast or financial outlook results and the variations may be material. No representation or warranty of any kind is or can be made with respect to the accuracy or completeness of, and no representation or warranty should be inferred from, our projections or the assumptions underlying them.

There can be no assurance that such information will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in this forward-looking information may differ materially from actual results or events. Because of the risks, uncertainties and assumptions contained herein, readers should not read forward-looking information as guarantees of future performance or results. Nothing in this presentation is, or should be relied upon as, a promise or representation as to the future. All amounts are in USD unless otherwise noted.

Accordingly, readers should not place undue reliance on forward-looking information. The forward-looking in this Presentation is made as of the date of this Presentation. MindMed disclaims any intention or obligation to update or revise such information, except as required by applicable law, and MindMed does not assume any liability for disclosure relating to any other company mentioned herein.

# The Time Is Now

MindMed Is In A Unique Position At A Catalytic Time In Drug Development History

## Our Thesis:

**Patients deserve more effective medicine and therapies for mental health and addiction**

**Untapped Value** : Psychedelics have not become medicines due to stigma, not the safety/efficacy profile


**Compounding All Of This** : Covid-19, joblessness and the autonomization of society

# Establishing A New Class Of Medicine For Mental Health

Psychedelic Inspired Medicines

## Development Principles:

- 1 **Patient First:** Focus on multiple significant unmet patient needs in mental health and addiction
- 2 **Industry Expertise:** Paramount pharmaceutical industry experience
- 3 **Data Moats:** Regulated clinical trials
- 4 **Diversify Pipeline:** Pipeline of compounds increases our total addressable market and likelihood of commercialization
- 5 **Collaborate:** Evaluate partnerships with biopharma companies to accelerate product development with non-dilutive capital
- 6 **Invest Early:** We aggressively explore accretive M&A opportunities while investing in pertinent mental health technologies



# Defining A New Asset Class

## Product Delivery Categories



### Non-Hallucinogenic

- LSD Microdosing for ADHD
- 18-MC for Addiction

#### HOW IT'S DONE

Derived from psychedelics, negligible hallucination effect

#### HOW IT'S DELIVERED

Doctor prescription  
Pharmacy pickup and take-home



### Hallucinogenic

- LSD Experiential Therapy for Anxiety
- LSD Experiential for Cluster Headaches

#### HOW IT'S DONE

A high dose or "experiential" dose of psychedelics

#### HOW IT'S DELIVERED

Overseen by therapist & doctor  
In-clinic treatment only

# FDA Is The Only Way

FDA Has Clear Regulatory Framework & Commercialization Pathway



## FDA View and Process:

- 1 File IND - Investigational New Drug
- 2 Approval by the Institutional Review Board
- 3 Conduct research under Schedule 1 License from the DEA (if compound is schedule 1)
- 4 Complete usual clinical trial process for approval

## Breakthrough Therapy Designation (BTD):

- Others have already received three designations in psychedelics

## Additional incentives for Opioid Use Disorder:

- Accelerated Approval/Breakthrough Designation for development of treatments for opioid use disorders
- Lowered threshold for approval

## Patients Already Being Dosed in Regulated Environments:


- Multiple ongoing clinical trials in the U.S. already at Johns Hopkins & NYU

# Big Pharma: Search and Acquire

Psychedelic Inspired Medicine has already been approved

## Major corporations are coming on board:

Johnson and Johnson SPRAVATO (Esketamine)  
Multiple indications approved by the FDA  
=\$1.5 Billion USD<sup>5</sup> in annual sales



## Institutional Interest & Investment in Psychedelics:

- Government: DARPA (\$27 million USD)<sup>30</sup>
- Big Pharma: Johnson & Johnson Phase 1 to Approval (Spravato)
- Universities: Johns Hopkins University (\$17 million USD)<sup>31</sup>, UCSF School of Nursing, NYU Langone School of Medicine

Bottom line: Nearly **\$525 million USD**<sup>33</sup> invested in first half of 2020, **projected to grow at 16.3%**<sup>32</sup> CAGR

# Markets Are Massively Underserved

Estimated \$100+ billion<sup>19</sup> global total addressable market for psychedelics

ANXIETY

**\$4.7B**

Global annual anxiety drug sales<sup>6</sup>

ADHD

**\$9.5B**

Global annual ADHD drug sales<sup>6</sup>

ADDICTION

**\$42B**

Substance abuse treatment market<sup>45</sup>

DEPRESSION

**\$9.6B**

Global annual depression drug sales<sup>6</sup>

According to national drug abuse data, overdoses have increased 42% since Covid-19<sup>39</sup>

Mental health experts find a strong link between loneliness/depression and drug overdoses<sup>40</sup>



# MindMed Is Collaborating With Leading Psychedelic Researchers

Clinical Researchers With Psychedelic Research Experience Are Rate Limiting Factors

## University Hospital Basel's Liechi Lab



- Acquired 10+ years of valuable research & data
- Most valuable LSD data for drug development
- 18 completed or ongoing clinical trials of psychedelics

## Maastricht University



- Leading research experts for microdosing of psychedelics
- Phase 2a Clinical Trial - Adult ADHD



**Professor Dr. Matthias Liechi, PhD & M.D.**

*Leader of Liechi Lab at University Hospital Basel*



**Dr. Kim Kuypers PhD**



**Dr. Peter Gasser M.D.**

*"Meet the Only Doctor in the World Legally Allowed to Use LSD to Treat Patients" - VICE*



**Matthew W. Johnson, PhD**

*Leading expert at Johns Hopkins University Center for Psychedelic Research*

# Investing in the Future of Medicine with NYU Langone Medical Center

Building critical infrastructure for bridging access to large groups of mental health professionals

## Long-term Commitment to Solving Mental Health Issues:

- MindMed is committing \$5 million USD over a five-year period
- Initial focus on substance use disorders including opioid addiction and alcoholism
- Catalyze efforts to recruit and train more psychiatrists and clinical investigators

## Managed by NYU's Seasoned Clinical Experts



### Michael Bogenschutz, M.D.

Primary investigator leading the effort towards FDA approval of psilocybin-assisted psychotherapy for Alcohol Use Disorder



### Stephen Ross, M.D.

World leader in advancing research on psychedelic medicine and a prominent addiction psychiatrist



NYU Langone Health and NYU  
Grossman School of Medicine

# Our Development Process

MindMed's Capital Efficient Corporate Strategy



# Broadest & Most Diversified Pipeline of Psychedelic Drugs in Clinical Development and R&D

Pipeline Diversification Offer Access To Full Spectrum Of Psychedelic Inspired Medicines



# Albert: The Digital Medicine Division for Psychedelics


AI spend in healthcare and pharma to increase four-fold by 2025<sup>46</sup>

## Can enhance all phases of the clinical paradigm:

- Development
- Diagnosis
- Monitoring
- Telehealth modalities
- Treatment
- Relapse prevention
- Adherence
- Remote clinical trials

## Real-World Results from Digital Medicine

- Potential \$70B USD in drug discovery savings by 2028<sup>47</sup>
- 28% improvement in adherence<sup>48</sup>
- Cut incorrect drug dosage intake by as much as 50%<sup>49</sup>



Pairing digital tools, such as wearables and the latest in machine learning, with psychedelic assisted therapies


# MindMed Discover

## MindMed IP & Pipeline Generator In Switzerland

# Creating Next-Gen Medicines & Delivery Methods


MindMed is working with the Liechti Lab to research and develop next-gen therapies, compounds, and dosing technologies

We have an exclusive license for DMT, MDMA, LSD and Psilocybin




**DMT**


Active ingredient in  
Ayahuasca



**MDMA**



**PSILOCYBIN**



**LSD**




 **Universitätsspital  
Basel**

Department of  
Biomedicine

# University Hospital Basel

Exclusive License To Multiple Ongoing Phase 1 & 2 Trials



\*Management estimates; actual timeline will depend on results, approvals and other factors outside of MindMed's control



# First Ever Clinical Trial Combining LSD & MDMA


Phase 1 Clinical Trial Evaluating LSD-MDMA Combination

## Clinical Trial Progress and Details:


Phase 1 LSD-MDMA trial is scheduled to start in Q1 of 2021 in Basel, Switzerland

## Purpose:

Evaluating if LSD & MDMA within the same session produces greater overall positive acute effects when compared to LSD or MDMA on their own



LSD



MDMA

# Invaluable & Protectable IP

## LSD Neutralizer:

- Shorten and stop LSD trips while giving the patient and therapist control
- MMED and UHB have filed a patent application in the US, which preserves worldwide rights

## Personalized dosing:

- Two patent applications covering MDMA dose optimization and LSD dose response - MMED has the exclusive global commercial rights
- Identifying best technologies to implement personalization techniques for patients



# Project Lucy

## LSD Assisted Therapy

# Next Up: The Xanax Crisis

Serving Those in Need While Breaking Obsolete Stigma

**284M**

Globally suffer from anxiety<sup>23</sup>

**36%**

of patients actually seek treatment<sup>15</sup>



Covid-19 Adding Fuel to the Fire

**ANTI-ANXIETY PRESCRIPTIONS**

**+34.1%**

Month-over-month increase<sup>20</sup>

**XANAX**

**+14.5%**

Year-over-year increase<sup>21</sup>

MindMed is developing a new approach to treat anxiety that is not a 'pill a day'

# From Problem Child To Wonder Child

LSD Is Relatively Non-Toxic, Stigma Is More Dangerous

## LSD May Be A Safer Alternative:

Safety profiles show LSD to be among the **least harmful drugs in the world** (Alcohol is most harmful)<sup>42</sup>

## Current medications have asymmetric Risk:Reward profiles

**Benzodiazepines are 2x more dangerous than LSD**,<sup>42</sup> yet 30 million people are prescribed them every year<sup>43</sup>

**LSD is not what you think:**  
Emergency Department visits involving illicit drugs, 2011<sup>37</sup>

Substance	ED Visits
Cocaine	505,224
Heroin	258,482
Cannabinoids	479,560
Amphetamines	159,840
LSD	<b>4,819</b>
% of Total ED Visits	<b><u>.34 of ED visits</u></b>


# MindMed Acquired Phase 2 Trial

Using Phase 2 Trial To Jumpstart a Potential Phase 2b LSD Trial For Anxiety Disorder


## Value through clinical trial acquisitions:



Acquired ongoing Phase 2 Anxiety clinical trial from UHB led by **Dr. Peter Gasser** & Dr. Matthias Liechti



## LSD Development Plan:



Based on industry averages, this saves roughly **\$8.4 to \$26.2 million USD** in non-dilutive financing costs and 4+ years of time<sup>29</sup>

Currently preparing to open the IND with a Phase 2 Study

Plan to file IND Q3 2021

# Addressing The Opioid Crisis

18-MC

# Time Is Now: Addiction Patients Need New Options

Existing Addiction Treatments Have Led to a \$2.5 Trillion USD Problem<sup>8</sup>

## \$700 Billion USD

Annual Cost of Opioid Use Disorder (OUD) to the United States<sup>8</sup>


## 92 M

Amount of People Using Prescription Opioids in the US<sup>7</sup>

## +395%

Increase in Overdose Deaths Involving Prescription Opioids 1999-2018<sup>3</sup>

### CMS Spend On OUD & Withdrawal Drugs (\$Millions) USD



Source: US Centers for Medicare & Medicaid Services



# The Problem Is Clear


Working Alongside The FDA for Potential Approvals

## New FDA Incentives for Opioid Treatments

- Accelerated Approval/Breakthrough Designation for development of treatments for opioid use disorders
- **New threshold for approval:**  
Patients can show signs of "fewer occasions per day" rather than total abstinence

# 88%

Even after 12 weeks of treatment with buprenorphine/naloxone, over 88% of patients relapse when drug therapy is tapered<sup>38</sup>




# Introducing 18-MC, Next Gen Addiction Therapeutic

18-MC focuses on fixing the problem, rather than covering it up

18-MC works as well as Ibogaine without the harmful side effects: non-hallucinogenic and non-cardiac toxic


- MindMed intends to apply for BTDD for 18-MC, which shortens the timeline for drug development and review by an average of 30%<sup>41</sup>

18-MC has been shown to be as effective than Ibogaine without the toxicity



# 18-MC Approaches Addiction Differently


Addressing Addiction as a Brain Disease




# 18-MC Development Plan

## Timeline Overview

### 18-MC Development Timeline



### Phase 2a Trial Design:



\*Management estimates; actual timeline will depend on results, approvals and other factors outside of MindMed's control

# LSD Microdosing Testing a Silicon Valley Trend

# Backed By Decades of Anecdotal Evidence

Using Sub-perceptual Amounts of LSD (Microdose)

Extensive anecdotal evidence suggests microdosing Psilocybin & LSD may:

- Increase focus
- Decrease anxiety
- Increase creativity
- Improve mood

**Sub-perceptual/Non-Hallucinogenic:**

- Microdose (Sub-perceptual): 10-25 ug LSD
- Limited rigorous science and clinical trials

# Generation Adderall Seeking New Options

Adults raised on stimulants need new options

## Math Doesn't Lie: The Problem is Getting Worse

- 16 million adult ADHD sufferers<sup>2</sup>
- 123% increase in prevalence<sup>25</sup>

## And Patients Need an Alternative

- 89.1% not receiving treatment<sup>11</sup>

“It’s ‘quite possible’ that low doses of LSD could have a stimulant effect by activating dopamine pathways in the brain. Like Adderall and Ritalin, it may excite the cerebral cortex, which controls high-order cognitive functions such as perception and sensation.”<sup>44</sup>



**DAVID NICHOLS**

*Professor of Pharmacology at Purdue University,  
Indiana*

# LSD Microdosing Phase 2a Clinical Trial

Proof of Concept - Entered into clinical trial agreements with Maastricht University and University Hospital Basel

Dr. Kim Kuypers will serve as Principal Investigator for Maastricht site



Dr. Matthias Liechti will serve as Principal Investigator for the Basel site



### Clinical Trial Progress and Details:

- Phase 2a anticipated to begin in Q3 2021 in Europe
- Low dose LSD (20 mcg) compared with a placebo administered for 6 weeks

### Locations

- Maastricht (Netherlands)





# Groundbreaking LSD Microdosing Study Using Digital Clinical Markers


Evaluating Benefits on Neuroplasticity, Sleep, Cognitive Enhancement Variables and Immune System Response on the Human Body

## Combining LSD & Digital to Understand Effects On:

- BDNF plasma levels
- Sleep measures
- Quality of life
- Mood
- Cognitive performance
- Immune system response

## World-Leading Researchers

- Led by [Dr. Kim Kuypers](#)



# Small Population - Horrific Problem

Phase 2a LSD Trial for Cluster Headaches, also known as "Suicide Headaches"

## Clinical Trial Progress and Details:

- Phase 2a began treating patients in Q2 2020
- Expected readout in Q4 2022
- LSD pulse regimen (3 x 100 µg LSD in three weeks) in 30 patients
- May evaluate a sub-population for orphan drug designation

## Potential for Near-term Value:

Orphan drug designation gives companies exclusive marketing and development rights to recoup R&D costs in rare disease treatment

# Team



**JR Rahn**

*Co-Founder, Director & Co-CEO*

JR is a former Silicon Valley tech executive. JR worked in market expansion and operations at Uber. After leaving Uber, he was backed by the Silicon Valley tech accelerator Y Combinator for his company Upgraded.



**Stephen L. Hurst, JD**

*Co-Founder, Executive Chair & Co-CEO*

Steve has more than thirty-five years' experience in the biopharmaceutical industry including work for The Immune Tolerance Institute, The Regents of the University of California, The World Bank and BIO Ventures for Global Health.



**Dr. Miri Halperin Wernli, PhD**

*President; Board Director; Head of Development Pipeline Programs & Digital Medicine*

Dr. Halperin Wernli previously worked in clinical psychiatry in Swiss academic hospital settings and then held various global senior leadership positions in the pharma and biotech industries in Switzerland and in the US (Merck, Sharp and Dohme, Roche and Actelion pharmaceuticals) covering Product Development, R&D, and Strategic Marketing.



**Carol Nast**

*Chief Operating Officer*

Carol has spent her career in executive level positions with large multinational companies and early stage companies in the medical industry. She is a recognized expert in product development and commercialization and has extensive experience in the management of complex, multinational partner programs and has lead successfully the development and commercialization of over 100 products.



**Jeanne Bonelle**

*EVP, Technical Operations*

Jeanne has established quality systems within the developmental phase for a wide range of products, including Senior Director of Quality Assurance at Inhale Therapeutic Systems, Inc., (now Nektar Therapeutics, Inc.); Director of Quality Assurance at Cholestech Inc. (now Alere Inc.); Manager of Quality Assurance at BioTrack, (now a subsidiary of Roche Diagnostics GmbH); Manager of Quality Assurance at BioResponse Inc. (now Baxter Health Care).



**Dave Guebert**

*Chief Financial Officer*

Dave Guebert is a CPA, qualified in both Alberta and Pennsylvania, and a Member of the Institute of Corporate Directors. He started his career in 1979 at Deloitte where he qualified for his CPA designations. He went on to serve as the Controller for the XV Olympic Winter Games from 1986 to 1988. Since then has taken on increasing senior roles, acting as Chief Financial Officer for a number of public and private companies, primarily in the technology industry.



**Donald Gehlert, PhD**

*Chief Scientific Officer*

Don has extensive experience in drug discovery and expertise in key functional areas of exploratory development and disease biology. During his career at Lilly, Don led or participated in teams that introduced 19 molecules into the Lilly pipeline including both small and large molecule therapies.



**Nico Forte**

*Senior Director, Business Operations and Development*


Nico has more than twenty-five years of marketing and business development experience primarily in the biopharma and medical device industries. His background includes B2B agency marketing and communication work for Bristol-Myers and Mead Johnson Oncology divisions as well as business development roles for Inhale Therapeutic Systems, Inc., (now Nektar Therapeutics, Inc.).



**Madeline Feldman**

*Director of Operations & Administration*


Madeline has a background supporting startups through corporate innovation and investor relations, fundraising for venture capital funds and non-profit organizations, and building out operational departments in various industries. She has a love for performing arts and works with artists in creating and producing stage shows for major venues and resorts.



**Collin Gage**

*Head of Corporate Development*

Collin began his career at Point72 Asset Management. From there, he worked at the Genjiko Family Office. While at Genjiko he was responsible for selecting and researching alternative investments, expansionary efforts, and capital management. Genjiko is the family office of a former Fortune 50 C-Level executive. During this period, Collin also helped co-found a biotech focused venture capital fund called Presight Capital.



**Shahera St. John**

*Vice President, Programs*

Shahera has nearly 20 years of project management experience. As an independent consultant, Ms. St. John supported companies of all sizes from start-up to Fortune 100 companies in biotech, pharma, and medical device. She has worked with various sized teams to help advance programs from early research/R&D through all phases of development, including Phase 3 and commercialization. Ms. St. John obtained her degree in Molecular, Cellular, and Development Biology from the University of California, Los Angeles.



**Carole Abel**

*Senior Director Clinical Operations & Program Leader LSD*

Carole has over 23 years of experience in multidisciplinary environments, including 15 years in the pharma industry in Switzerland (Actelion Pharmaceuticals and Creso Pharma). She has been successfully leading cross-functional teams and directing groups in different areas: operations, project management, and process improvements. Over the last few years, Carole has been instrumental in the preparation and coordination of corporate audits and due diligence activities.


# Board of Directors

## JR Rahn

Co-Founder, Director & Co-CEO



JR is a former Silicon Valley tech executive. JR worked in market expansion and operations at Uber. After leaving Uber, he was backed by the Silicon Valley tech accelerator Y Combinator for his company Upgraded.



## Bruce Linton

Director



An Activist Investor with SLANG Worldwide Inc. (CSE:SLNG). Activist Investor with OG DNA Genetics Inc Founder and Former Chairman and CEO of Canopy Growth Corporation (CGC/WEED). Bruce chairs the board's Compensation, Governance and Nomination Committee.



## Stephen L. Hurst, JD

Co-Founder, Chairman and Co-CEO



Steve has more than thirty-five years' experience in the biopharmaceutical industry including work for The Immune Tolerance Institute, The Regents of the University of California, The World Bank and BIO Ventures for Global Health.



## Brigid Makes

Director, Chair of Audit Committee



Served as Senior Vice President and Chief Financial Officer of Miramar Labs. Former CFO for Nektar Therapeutics (formerly Inhale Therapeutics) B.A. in Finance and International Business from McGill University and an M.B.A. from Bentley University. Brigid chairs the board's Audit Committee.



## Stanley D. Glick, PhD

Inventor 18-MC, Chair of Scientific Advisory Board, and Director



Former Professor of Pharmacology at Mount Sinai School of Medicine. Chaired the pharmacology and neuroscience program at Albany Medical College. Co-inventor of a novel group of agents (iboga alkaloid congeners) for treating drug addiction, including 18-methoxycoronaridine (18-MC).



## Dr. Miri Halperin, PhD

President, Director



Dr. Halperin Wernli previously worked in clinical psychiatry in Swiss academic hospital settings and then held various global senior leadership positions in the pharma and biotech industries in Switzerland and in the US (Merck, Sharp and Dohme, Roche and Actelion pharmaceuticals) covering Product Development, R&D, and Strategic Marketing.



## Perry Dellelce

Director



Managing partner of Wildeboer Dellelce LLP. Chair of the NEO Exchange, Canada's newest stock exchange. Board Member of Mount Logan Capital Inc. and Lendified Inc.



# Scientific Advisory Board



**Stanley D. Glick, PhD**  
*Director and Chair Scientific Advisory Board*



**John Rotrosen, MD**  
*Professor of Psychiatry NYU Langone*



**Kenneth Alper, MD**  
*Clinical Associate Professor of Psychiatry and Neurology*



**Sarah McCallum, PhD**  
*Associate Professor of Neuroscience and Experimental Therapeutics*



**Matthew W. Johnson, Ph.D**  
*Professor at Johns Hopkins*



**Jed Rose, PhD**  
*Professor in Psychiatry and Behavioral Sciences at Duke University*



**John Blacker, PhD**  
*Professor of Process Chemistry, University of Leeds*



**Natalie Wheeler, PhD**  
*Medical Science Liaison with Dova Pharmaceuticals*




**Eric Edwards, MD, PhD**  
*Co-founder and Member, Board of Directors at Kaleo, Inc.*




# Near Term Inflection Points For MMED

MindMed Is Capitalizing On Opportunity



## Inflection Points:



\*Management estimates; actual timeline will depend on results, approvals and other factors outside of MindMed's control

# NEO: MMED // OTCQB: MMEDF // DE: MMQ

First Publicly Listed Psychedelic Biotech Company

Share Ownership (As of 1/7/2021)		
Executive Team/Directors/Insiders	77,324,114	17.8%
Non-insider shares	306,694,081	70.8%
Equity Incentive Plan (Issued)	22,592,427	5.2%
Outstanding Warrants	26,680,875	6.2%
Total	433,291,497	100%
Number of Shareholders	30,000+	

## \$184M

USD Raised since inception  
(including warrants)

### Strong investor backing

- Seed Round Aug '19: \$6m USD
- Pre-Public Feb '20: \$24m USD
- Bought Deal Financing May '20: \$10m USD
- Bought Deal Financing Oct '20: \$22m USD
- Bought Deal Financing Dec '20: \$27m USD
- Bought Deal Financing Jan '21: \$72m USD




Market Cap CAD: \$1.8 billion January 7th (\$4.21 price per share)



Market Cap USD: \$1.4 billion January 7th (\$3.21 price per share)

# Appendix

- 41 **Mindmed in the News**
- 42 **Sources**





# Mindmed in the News

## THE WALL STREET JOURNAL.

*"Psychedelics-Drug Startup Raises \$24 Million Ahead of IPO." February 27, 2020*

## Bloomberg

*"Its market capitalization of over C\$1 billion puts the company ahead of at least eight companies in Canada's benchmark S&P/TSX Composite Index, according to data compiled by Bloomberg." December 9, 2020*

## BUSINESS INSIDER

*"A startup that wants to use psychedelics to treat addiction just raised \$6.2 million from the host of Shark Tank and the architect behind the world's biggest cannabis grower" Sep 30, 2019*

## FASTCOMPANY

*"This could save lives, cure depression, help alcoholism, get people off opioids—why wouldn't I want to be invested?" -Kevin O' Leary  
December 9, 2019*

## THE NEW YORKER

*"New York is getting its first psychedelic-medicine center, with the help of a startup called MindMed, which develops hallucinogens to treat mental illness and addiction, and is funding an institute at N.Y.U. Langone Medical Center." October 12, 2020*

## FORTUNE

*"Psychedelic drugs may transform mental health care. And big business is ready to profit from the revolution." February 17, 2020*

## Forbes

*"Psychedelic Drug Company MindMed Applies For Nasdaq Up-Listing" September 25, 2020*

## TOWN&COUNTRY

*"The evidence for psychedelics as medicine is far greater than that for CBD, which companies are selling to relieve ills from Parkinson's to Crohn's." April 13, 2020*



CBINSIGHTS

**"MindMed named one of 36 startups that could change the world" December 17, 2019**

# Sources

1. Anxiety and Depression Association of America, Facts & Statistics,
2. Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD)
3. Overdose Death Rates. (2020, August 25). National Institute on Drug Abuse. [https://www.drugabuse.gov/drug-topics/trends-statistics/overdose-death-rates#:~:text=Drug%20overdose%20deaths%20involving%20prescription,\(Source%3A%20CDC%20WONDER\).](https://www.drugabuse.gov/drug-topics/trends-statistics/overdose-death-rates#:~:text=Drug%20overdose%20deaths%20involving%20prescription,(Source%3A%20CDC%20WONDER).)
4. The National Institute of Mental Health, Prevalence of Major Depressive Episode Among Adults
5. Goldman Sachs. (2019, May). Americas Healthcare: Pharmaceuticals.
6. IQVIA. (2020, June). IQVIA Global Annual Sales Report.
7. Azadfar M, Huecker MR, Leaming JM. Opioid Addiction. [Updated 2020 Aug 14]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK448203/>
8. The Council of Economic Advisers (CEA), The Full Cost of the Opioid Crisis, October 2019
9. SAMSA, Results from the 2018 National Survey on Drug Use and Health
10. Doshi, J. A., Hodgkins, P., Kahle, J., Sikirica, V., Cangelosi, M. J., Setyawan, J., Erder, M. H., & Neumann, P. J. (2012). Economic Impact of Childhood and Adult Attention-Deficit/Hyperactivity Disorder in the United States. *Journal of the American Academy of Child & Adolescent Psychiatry*, 51(10), 990-1002.e2. <https://doi.org/10.1016/j.jaac.2012.07.008>
11. Kessler, R. C., Adler, L., Barkley, R., Biederman, J., Conners, C. K., Demler, O., Zaslavsky, A. M. (2006). The Prevalence and Correlates of Adult ADHD in the United States: Results from the National Comorbidity Survey Replication. *American Journal of Psychiatry*. 163, 716-723. doi:10.1176/appi.ajp.163.4.716. Retrieved from: [https://ajp.psychiatryonline.org/doi/full/10.1176/ajp.2006.163.4.716?url\\_ver=Z39.88-2003&rft\\_id=ori:rid:crossref.org&rft\\_dat=cr\\_pub%3dpubmed](https://ajp.psychiatryonline.org/doi/full/10.1176/ajp.2006.163.4.716?url_ver=Z39.88-2003&rft_id=ori:rid:crossref.org&rft_dat=cr_pub%3dpubmed)
12. Chung W, Jiang S, Paksarian D, et al. Trends in the Prevalence and Incidence of Attention-Deficit/Hyperactivity Disorder Among Adults and Children of Different Racial and Ethnic Groups. *JAMA Netw Open*. 2019;2(11):e1914344. doi:<https://doi.org/10.1001/jamanetworkopen.2019.14344>
13. Konnopka, A., & König, H. (2020). Economic Burden of Anxiety Disorders: A Systematic Review and Meta-Analysis. *PharmacoEconomics*, 38(1), 25–37. <https://doi.org/10.1007/s40273-019-00849-7>
14. Bandelow, Borwin, and Michawlis, Sophie. "Epidemiology of anxiety disorders in the 21st century." *Dialogues in Clinical Neuroscience*, Sep 2015, <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4610617/>
15. ADAA. (n.d.). Facts & Statistics. <https://adaa.org/>. Retrieved June 25, 2020, from <https://adaa.org/about-adaa/press-room/facts-statistics#:~:text=Anxiety%20disorders%20are%20the%20most,of%20those%20suffering%20receive%20treatment>.
16. Hirschler, B. (2013, January 3). Analysis: Entering the age of the \$1 million medicine. U.S. <https://www.reuters.com/article/us-rare-diseases/analysis-entering-the-age-of-the-1-million-medicine-idUSBRE9020C120130103>
17. Wei, D. Y., Yuan Ong, J. J., & Goadsby, P. J. (2018). Cluster Headache: Epidemiology, Pathophysiology, Clinical Features, and Diagnosis. *Annals of Indian Academy of Neurology*, 21(Suppl 1), S3–S8. [https://doi.org/10.4103/aian.AIAN\\_349\\_17](https://doi.org/10.4103/aian.AIAN_349_17)
18. Elli Lilly. (2018, January). Migraine Impact Report. [https://www.multivu.com/players/English/8259051-lilly-migraine-impact-report/docs/ExecutiveSummary\\_1516320372594-121193785.pdf](https://www.multivu.com/players/English/8259051-lilly-migraine-impact-report/docs/ExecutiveSummary_1516320372594-121193785.pdf)
19. Eight Capital. (2020, April). Taking a trip into commercializing psychedelic medicine.
20. Petersen, A. (2020, May 25). More People Are Taking Drugs for Anxiety and Insomnia, and Doctors Are Worried. *WSJ*. <https://www.wsj.com/articles/more-people-are-taking-drugs-for-anxiety-and-insomnia-and-doctors-are-worried-11590411600>
21. IQVIA. (2020a, April). IQVIA 2020 Drug Sales Report. <https://analyticslink.customerportal.iqvia.com/app/#/>
22. Delveinsight. (2020, January). Market Insights, Epidemiology, and Market Forecast—2030.
23. Ritchie, H. (2018, January 20). Mental Health. Our World in Data. <https://ourworldindata.org/mental-health#:~:text=Globally%20an%20estimated%20284%20million,experience%20anxiety%20disorders%20than%20men>.
24. The National Institute of Mental Health Information Resource Center, Prevalence and correlates of prescription stimulant use, misuse, use disorders, and motivations for misuse among adults in the U.S.
25. Chung W, Jiang S, Paksarian D, et al. Trends in the Prevalence and Incidence of Attention-Deficit/Hyperactivity Disorder Among Adults and Children of Different Racial and Ethnic Groups. *JAMA Netw Open*. 2019;2(11):e1914344. doi:10.1001/jamanetworkopen.2019.14344
26. Faraone SV, Spencer TJ, Montano CB, Biederman J. (2004). Attention-Deficit/Hyperactivity Disorder in Adults: A Survey of Current Practice in Psychiatry and Primary Care. *Arch Intern Med*.164(11):1221–1226. doi:10.1001/archinte.164.11.1221. Retrieved from: <https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/217065>,
27. Schuman, M. C. H. A. M. (2020, August 18). Multiple states say the opioid crisis cost American economy over \$2 trillion. *CNN*. <https://edition.cnn.com/2020/08/18/us/opioid-crisis-cost-united-state-2-trillion-dollars/index.html>
28. Sertkaya, A., Wong, H. H., Jessup, A., & Beleche, T. (2016). Key cost drivers of pharmaceutical clinical trials in the United States. *Clinical trials (London, England)*, 13(2), 117–126. <https://doi.org/10.1177/1740774515625964>
29. Roth Leads \$26.9 Million Project to Create Better Psychiatric Medications — News Room - UNC Health and UNC School of Medicine. (2020, June). <http://News.Unhealthcare.Org/>. <http://news.unhealthcare.org/news/2020/june/roth-leads-26-9-million-project-to-create-better-psychiatric-medications>
30. Johns Hopkins Launches Center For Psychedelic Research. (2019, September 4). Johns Hopkins Medicine Newsroom. <https://www.hopkinsmedicine.org/news/newsroom/news-releases/johns-hopkins-launches-center-for-psychedelic-research>
31. Databridge Market Research. (2020, January). U.S. Psychedelic Drugs Market is Expected to Grow at 16.3% in the Forecast Period of 2020 to 2027.
32. NEO Stock Exchange. (2020, May). The Report on Psychedelics Volume 1. <https://reportonpsychedelics.com/report2020/>
33. Gasser, P., Holstein, D., Michel, Y., Doblin, R., Yazar-Klosinski, B., Passie, T., & Brenneisen, R. (2014). Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. *The Journal of nervous and mental disease*, 202(7), 513–520. <https://doi.org/10.1097/NMD.0000000000000113>
34. Henning, E. H. (2020, August). Magic Mushroom Drug-Backer Compass Pathways Files for U.S. IPO. *Bloomberg.Com*. <https://www.bloomberg.com/tosv2.html?vid=&suuid=29ea47e0-f442-11ea-9abd-73452a178f4f&url=L25ld3MvYXJ0aWNsZXRMjAyMC0wOC0yOC9tYWpY1tdXNocm9vbS1kcVnLWJhY2tldi1jb21wYXNzLXBhdGh3YXlzLWZpbGVzLWZvci11LXMtaXBw>
35. Stockhouse. (2019, August). Why Psychedelics Look like the Next Billion-Dollar Business. *Stockhouse.Com*. <https://stockhouse.com/news/newswire/2019/08/23/why-psychedelics-look-like-next-billion-dollar-business>
36. Sidney Cohen, S. C. (1960). Lysergic acid diethylamide - Side effects and Complications. *The Journal of Nervous and Mental Disease*
37. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES. (2013, May). Drug Abuse Warning Network, 2011: National Estimates of Drug-Related Emergency Department Visits. <https://www.samhsa.gov/data/sites/default/files/DAWN2k11ED/DAWN2k11ED/DAWN2k11ED.pdf>
38. Ling, W., Hillhouse, M., Domier, C., Doraimani, G., Hunter, J., Thomas, C., Jenkins, J., Hasson, A., Annon, J., Saxon, A., Selzer, J., Boverman, J., & Bilangi, R. (2009). Buprenorphine tapering schedule and illicit opioid use. *Addiction (Abingdon, England)*, 104(2), 256–265. <https://doi.org/10.1111/j.1360-0443.2008.02455.x>
39. DMAP. (2020). THE CONSEQUENCES OF COVID-19 ON THE OVERDOSE EPIDEMIC: OVERDOSES ARE INCREASING. *HIDTA*. <http://www.odmap.org/Content/docs/news/2020/ODMAP-Report-May-2020.pdf>
40. Hosseinbor, M., Yassini Ardekani, S. M., Bakhshani, S., & Bakhshani, S. (2014). Emotional and social loneliness in individuals with and without substance dependence disorder. *International journal of high risk behaviors & addiction*, 3(3), e22688. <https://doi.org/10.5812/ijhrba.22688>
41. Canaccord Genuity. (2020, September). Open your mind to a new kind of medicine. *Canaccord Genuity Capital Markets*.
42. Nutt, David & King, Leslie & Phillips, Lawrence. (2010). Drug harms in the UK: A multi-criterion decision analysis. *Lancet*. 376.
43. Research suggests benzodiazepine use is high while use disorder rates are low. (2020, May 5). National Institute on Drug Abuse. <https://www.drugabuse.gov/news-events/science-highlight/research-suggests-benzodiazepine-use-high-while-use-disorder-rates-are-low>
44. Solon, O. (2019, May 21). Under pressure, Silicon Valley workers turn to LSD microdosing. *WIRED UK*. <https://www.wired.co.uk/article/lsd-microdosing-drugs-silicon-valley>
45. Marketdata Enterprises Inc. (2020, January). The US Addiction Rehab Industry.
46. Jye Su, L. S. (2020, April). Taking Stock of COVID-19: The Short- and Long-Term Ramifications on Technology and End Markets. *ABI Research*.
47. B. (2018). Artificial Intelligence in Drug Discovery Market Size Analysis and Opportunity, 2018-2028. *Bekryl Market Analysts*. <https://bekryl.com/industry-trends/ai-artificial-intelligence-in-drug-discovery-market-size-analysis>
48. AiCure announces new study results demonstrating 90% adherence from Phase 2 Abbvie study – AiCure. (2016, September 26). <https://aicure.com/>. <https://aicure.com/news/aicure-announces-new-study-results-demonstrating-90-adherence-phase-2-abbvie-study/>
49. Machine-learning algorithm cuts drug doses by as much as 50% for glioblastoma patients. (2018). *Radiology Business*. <https://www.radiologybusiness.com/topics/artificial-intelligence/machine-learning-algorithm-cuts-drug-doses>



**MindMed**